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Microchimerism is the presence of cells from one individual in another genetically distinct individual. Pregnancy is the main cause
of natural microchimerism through transplacental bidirectional cell traﬃcking between mother and fetus. The consequences of
pregnancy-related microchimerism are under active investigation. However, many authors have suggested a close relationship
linking fetal microchimerism and the development of autoimmune diseases. It has been more than ten years now since the
demonstration of the presence of a signiﬁcant high number of fetal microchimeric cells residing in thyroid glands from operated
patients with Graves’ disease. This intrathyroidal fetal microchimerism is an attractive candidate mechanism for the modulation
of Graves’ disease in pregnancy and the postpartum period.
1.Introduction
Microchimerism is deﬁned by the presence of alien cells
within an individual tissue with genetically diﬀerent back-
ground [1]. Microchimeric cells have two possible origins:
natural and artiﬁcial. Examples of the former are pregnancy,
miscarriage, and twinning or sexual intercourse, whereas the
most common cases for the later are tissue transplant or
blood transfusion. Pregnancy is the major source of natural
microchimerism.
Contrary to previous expectations, the placental tropho-
blastic physical barrier eﬀect is not a perfect cutoﬀ system.
A certain cell leakage is present between mother and fetus
during gestation, and this transplacental cell traﬃcking is a
two-way process. Fetal cells movement into maternal circu-
lation starts very early during pregnancy. Circulating fetal
cellshavebeen foundin maternalblood assoon asthefourth
week of gestation [2], whereas maternal microchimerism has
been detected in a newborn thyroid autopsied at day 2, but
so far has not been reported in thyroid diseases [3]. Earlier
evidences concluded that fetal cells transfer into maternal
circulation was more intense than maternal cells into fetal
blood[4].However,subsequentinvestigationsestimatedthat
fetus-to-maternaltransfershouldbeasfrequentasmaternal-
to-fetus traﬃcking because maternal DNA has been detected
in 40–100% of cord blood samples when polymerase chain
reaction (PCR) techniques were used [5, 6]. The extent of
this phenomenon is universal since fetal cells can be found
in the peripheral blood of almost 100% of women during
pregnancy[7].Althoughthelevelofcirculatingcellshasbeen
reported to be very low (1:500,000 fetal:maternal cells) [8],
such fetal cells can remain after delivery for more than 38
years postpartum [9]. The most plausible explanation for
this long cell persistence is that fetal microchimeric cells can
engraft into maternal bone marrow and provide a renewing
source of fetal cells in maternal blood for decades after de-
livery [10].
So far, only thehuman leukocyte antigen (HLA) compat-
ibility between mother and fetus has been identiﬁed as a
factor inﬂuencing the persistence of microchimeric cells.
Microchimerismandchronicgraftversushostdiseaseresem-
ble each other. Both diseases share many clinical and
pathological features with autoimmune diseases. Since auto-
immune disease are more frequent in childbearing age
females, it has been hypothesized that fetal microchimerism
maybe involved in their etiology. For a successful pregnancy,
the maternal immune system must not overreact to the fetus.
Dramatic changes throughout gestation make possible ma-
ternal tolerance of the fetus and permit fetal cells to move
into maternal circulation and settle in maternal tissues. As a2 Journal of Thyroid Research
Figure 1: Pregnancy is the major source of natural microchim-
erism. Pregnancy related microchimerism results from deﬁciencies
in the natural placental physical barrier tissue that divide the
maternal circulation from the fetal circulation. As a consequence,
there is mutual and bidirectional maternal and fetal cell traﬃc
during pregnancy. Microchimeric cells enter the circulation and
persist for many years in the host tissues. These cells are tolerated
while acquire speciﬁc and diverse biological actions. (Copy of
Figure5 in [1]).
result, maternal tolerance allows the persistence of fetal mi-
crochimerism (Figure 1).
Intrathyroidal fetal microchimerism has been reported
using diﬀerent techniques. PCR-based analysis identiﬁes Y-
chromosomal and merely demonstrates the presence of male
cells in maternal tissues [11, 12]. Other methodologies, such
as immunohistochemistry, ﬂuorescence in situ hybridization
(FISH) and HLA typing identify location, cellular progeny,
and immunogenic properties of microchimerism in diﬀerent
tissues [13, 14].
2. Effects of Microchimerism
According to cellular characterization, fetal microchimeric
cells could cover a wide spectrum of action. Experimental
data support a variety of important hypotheses concerning
their biological implications. The types of cells crossing the
placenta into the mother include both immune cells and
cytokeratin-positive epithelial cells. Such cells have been
identiﬁed as hematopoietic progenitor cells, nucleated ery-
throcytes, trophoblast cells, and leukocytes [15]. Therefore,
microchimeric cells could potentially operate as eﬀectors’
cells or as targets of an immune response. Other possibilities
include reactivity of microchimeric T-cell clones to the non-
shared maternal human leukocyte antigen (HLA) antigens
and presentation of microchimeric peptides by one host cell
to another host cell [16].
We have previously proposed a three-role division for
fetal microchimerism, which covers pathogenic, beneﬁcial,
and neutral microchimerism [1]. The concept of pathogenic
microchimerism initially suggested by Nelson [17], hypoth-
esizes that fetal cells following gestation may lead to a graft
versus host-like reaction in women. Accordingly, maternal
immune response to these foreign cells may support an auto-
immune reaction. It is also plausible the existence of a bene-
ﬁcial microchimerism, where persistent fetal cells may have a
beneﬁcialeﬀectasanewsourceofprogenitorcellspotentially
capabletocontributetomaternaltissuerepairprocesses.The
third possibility could be neutral microchimerism, where fetal
cells may act as innocent bystanders playing no role in biol-
ogy at all.
Inlinewithourproposedmicrochimericfetalcellsvaried
eﬀects, Fugazzola et al. [10] have recently speculated about
three new possible roles of these foreign cells in relation with
cancer, which are cell cancer destruction, tissue repair, and
promotion of cell cancer progression. Apparently, a given
fetal cell could act diﬀerently according to the particular
tissue environment or depending on the type of malignancy.
3.Immune Changes duringPregnancy
For a successful pregnancy, the maternal immune system
must not overreact to the fetus. The mechanisms through
which the immune systems between mother and fetus inter-
act to induce and maintain this immune tolerance are not
fully understood, but several changes have been described.
Trophoblast cells serve both as physical barrier as well as im-
mune modulator by expressing several molecules and secret-
ing speciﬁc cytokines. This involves the expression of Fas-
ligand, cytokines, indoleamine 2,3-dioxygenase, immune-
modulating sex steroids, and HLA-G. Fas-ligand is involved
in the removal of maternal T-cell clones that react to fetal
antigens. In animal models, indoleamine 2,3-dioxygenase
catabolizes tryptophan from maternal immune cells in the
placental area, which is essential for a successful pregnancy
in murine models, whereas HLA-G, exclusively expressed
on trophoblast cells, inhibits natural killer cell-mediated
cellular immunity [11].
These changes also include a reduction of T-regulatory
cells activity and aﬀect maternal T-helper (Th) cell dif-
ferentiation. Placental immune modulation promotes sup-
pression of Th1 (cellular), whereas relative enhancement of
Th2 (humoral) immunity occur. Thus placental immune
suppression helps establish fetal microchimerism. Immune
tolerance to fetal implant allows pregnant woman to accept
fetal circulating cells [14]. Consequently, once fetal cell
migrate and take up residence in maternal tissues, they may
survive.Thisimmunesuppressionmayremainsomemonths
after delivery [18], allowing fetal cells to establish themselves
and to survive the postpartum period [19]. Such dramatic
changes throughout gestation make possible maternal toler-
ance of the fetus and permit fetal cells to move into mater-
nal circulation and settle in maternal tissues. As a result,
maternal tolerance allows the persistence of fetal microchim-
erism.Journal of Thyroid Research 3
This complex modulation of the maternal immune
system by pregnancy is also reﬂected by the variation of cir-
culating levels of autoantibodies. Furthermore, there is com-
pelling evidences that circulating thyroid autoantibodies are
predictors for the increased risk of pregnancy complications
like miscarriage, breech presentation, or prematurity [20].
Probably thyroid autoimmunity represents a more profound
abnormal immune state, which induces an unstable implant
[21]. For instance, a recent Italian study showed that 37.2%
of thyroid peroxidase (TPO) antibody-positive women had
postpartum thyroiditis, versus 1.7% of the TPO antibody-
negative women. Furthermore, 20% of the TPO antibody-
positive women remained hypothyroid at the end of the
ﬁrst postpartum year versus 1% of TPO antibody-negative
women [22]. Another classic study described that up to 60%
of reproductive Graves’ disease women reported the onset of
the disease within one year after delivery [23].
At the same time, it has been hypothesized that preg-
nancy-related immune changes have important positive
eﬀects for the fetal immune system. There is evidence sug-
gesting that maternal immune cells instruct fetal cells how
to balance the requirement for self-defense on one hand
and the need for immunologic tolerance on the other. There
is still much to understand about tolerogenic versus immu-
nogenic forms of microchimerism, both of which have been
reported [24].
Taken together, these diﬀerent observations a question
may be raised whether the sequence of events in autoimmu-
nity is at least partly due to alloimmunity rather than auto-
immunity.
4.PregnancyandAutoimmuneDiseases
It is well recognized the highest prevalence of autoimmune
diseases in childbearing-age women than in men. It is also
well known that autoimmune diseases have a profound
inﬂuenceonpregnancyoutcome[19,25–27].Hormonaland
genetic factors are probably involved, but a clear explanation
for this type of preponderance is currently lacking. However,
the role of fetal microchimerism as a contributing factor for
the starting or maintenance of the autoimmune reaction in
women is an attractive hypothesis [1].
Fetal cells have been found not just in peripheral blood
but also within a variety of damaged tissues, where the
autoimmune reaction is taking place [11, 28–31]. The pres-
ence of activated immune fetal cells within the maternal tis-
sues may trigger susceptible women to develop autoimmune
disorders. As the placental-induced immune suppression is
vanished, the fetal immune cells may indeed become acti-
vated and initiate the autoimmune reaction [19]. The cause
of this relationship has been based on the degree of HLA dis-
crepancy between host and alien cells which may determine
the status of any potential graft versus host reaction.
On the other hand, it should be emphasized that a
positive eﬀect of pregnancy on autoimmune disease is gen-
erally observed. As previously mentioned, the placenta
induces immune suppression and so lessens autoimmune
activity. Actually, the amelioration of autoimmune clinical
manifestations along gestation is a usual clinical observation.
Experimental data suggest that, despite the relative enhance-
ment of Th2 reaction, both arms of the immune response
(Th1 and Th2) are globally reduced during pregnancy. The
observation is supported by the increase in T-regulatory cells
observed in pregnancy and because autoantibodies greatly
decrease during pregnancy [32].
Assuming that part of microchimeric fetal cells could be
progenitor cells of the fetal immune system, the pathogenic
eﬀect of fetal microchimeric cells in autoimmune diseases
canbeperpetuated.Thesecellscouldsurviveinbonemarrow
or move to maternal diﬀerent organs, where they could
proliferate, diﬀerentiate, and activate. The activation of fetal
immature T cells, monocytes, macrophages, and natural
killercellsandtheproductionofinﬂammatorycytokinesand
chemokines are believed to initiate then autoimmune dis-
eases [33, 34]. Alternatively, these cells could be recognized
as partially alloimmune and in consequence give rise to the
autoimmune reaction [10].
Finally, this potential association is also supported by the
observation that, albeit with few exceptions, the resetting to
normal immune status in the postpartum period is usually
coincidental with a clinical exacerbation of many autoim-
mune diseases.
5. Microchimerismand Autoimmune
Thyroid Disease
Several evidences have shown that female subjects with
autoimmune thyroid diseases frequently have microchimeric
fetal cells residing within their thyroid glands [3, 11, 12].
This has been described both in animals [27, 35]a n d
in humans [11, 12, 14, 36, 37]. Whether the presence
of fetal cells increases maternal thyroiditis or a previous
episode of thyroiditis increases the recruitment of these fetal
cells remains unknown. A number of studies revealed this
association demonstrating that the prevalence of male cells
is higher in women with autoimmune thyroid diseases who
previously had given birth to a son than in women without
autoimmune thyroid diseases who previously had given
birth to a son [10, 14]. These results generate the attractive
hypothesis of a causal relationship between microchimerism
and autoimmune thyroid diseases.
Davies’ laboratory has extensively investigated the inﬂu-
ence of pregnancy in autoimmune thyroid diseases, includ-
ing the relationship between fetal microchimerism and
autoimmune thyroid diseases [27, 35]. The group initially
found that experimental autoimmune thyroiditis in mice
enhanced the accumulation of intrathyroidal fetal cells
during pregnancy [35]. The murine model of experimental
autoimmune thyroiditis was established in female mice
using murine thyroglobulin (Tg) as antigen. Tg-treated mice
developedaﬂoridlymphocyticinﬁltrationby4–6weeksafter
immunization[27].Inaddition,theresultsshowedthatthere
were no signiﬁcant diﬀerences in thyroid function between
nonimmunized and Tg-immunized pregnant mice.
Davies’ group, going forward in the study of fetal
microchimerism as a cause involved in the development4 Journal of Thyroid Research
of autoimmune thyroid disease, used their experimen-
tal autoimmune thyroiditis model using sex-determining
region Y (SRY) gene as the marker of presence of male
microchimeric cells within maternal thyroids. The results
demonstrated the presence of fetal cells in 46% of Tg-
immunized pregnant mice, whereas few male fetal cells were
detected in only 20% of controls or nonimmunized pregnant
mice. Subsequent studies of cell characterization revealed
the immune origin of the cells that accumulate within the
thyroid of mice with experimental autoimmune thyroiditis
during pregnancy and early postpartum [35]. These fetal
cells were identiﬁed as regulatory and cytotoxic CD4+
(in a signiﬁcant proportion), CD11c+, and weakly CD8+,
but not from B220/CD45R+, CD11b+, or Sca-1+, which
indicates that intra-thyroidal fetal cells included T-cell and
dendritic cell lineage. This was accompanied by high titers of
antibodies to Tg. Furthermore, mice postpartum followup
revealed that intra-thyroidal fetal cells were most easily
seeninexperimentalautoimmunethyroiditisanimalsduring
pregnancy, whereas the presence of these cells decreased in
the postpartum period. So, a fetal cell-induced modulation
during pregnancy and postpartum was highly feasible.
As aforementioned, several clinical studies have found
malecellsinthyroidsamplesofwomenpreviouslydiagnosed
of Hashimoto’s thyroiditis [12–14, 37] .T h ep r e s e n c eo f
alien cells in autoimmune involved thyroids ranged between
38 and 83%. This wide spectrum of percentages probably
reﬂects the discrepancies in study design. Interestingly, the
percentage diﬀerences between the Hashimoto’s thyroiditis
and control groups in individual studies are constant.
Although the presence of fetal microchimerism was not
identiﬁedinnormalthyroidsorpatientswithnodulargoiters
by all authors [12, 13], nowadays it is considered that
microchimeric cells are present in normal glands and around
20% of follicular adenomas [10]. A recent Italian report
has revealed fetal microchimeric cells in normal maternal
thyroid tissue [38]. The authors explain the discrepancy
due to the diﬀerent origin of normal samples, from the
normal tissue contralateral, to a neoplastic lesion. This
ﬁnding further supports the idea that, in the presence of
a neoplastic process, microchimeric cells could migrate to
the thyroid and participate in the repair process [38]. All
in all, these results indicate a higher number of fetal micro-
chimeric cells in autoimmune thyroid diseases than in nor-
malthyroidsorbenignproliferativedisorders[11,14,19,37].
Therefore taken together, these ﬁndings strongly support a
possible pathogenic role for fetal microchimeric cells in the
development autoimmune thyroid disease. However, there
is still an important missing link that is the presence of
maternal microchimerism in male patients with Graves’
disease, which has been poorly studied.
6. Fetal MicrochimerismandGraves’ Disease
6.1. Graves’ Disease in Pregnancy. Pregnancy-related factors
have a strong inﬂuence in Graves’ disease [25]. Normally,
the clinical course of Graves’ disease improves as pregnan-
cy progresses, paralleling the reduction in serum TSH
receptor (TSH-R) autoantibodies level. The reﬂection of
this clinical improvement could be not only the quantity
of serum anti-body concentration but also the quality (or
the biological action) of these antibodies. Some authors
have hypothesized that the equilibrium between TSH-R
antibodies blocking and stimulating activities may shift
in favor of blocking antibodies [39], though not all the
experts share this opinion [40]. In any event, a ﬂuctuant
Graves’diseaseclinicalevolutionisacommonﬁndingduring
pregnancy with exacerbation during approximately the ﬁrst
three months and improvement in the last trimester [41].
In the postpartum period as the pregnancy-associated
immune-privileged state disappears, a relapse, exacerbation,
or new onset of Graves’ disease may occur. This outbreak
normally happens between 4–12 months after delivery [42].
In fact, epidemiological studies show that around 60% of
childbearing age women develop Graves’ disease during the
ﬁrst year after delivery [29, 43], whereas the frequency of
relapses varies from 30% to 70% of cases [44]. Likewise, an
increased risk of developing Graves’ disease after pregnancy
maybegreaterinolderpatients(>35years),andthisrisklasts
for several years after delivery [21, 45].
6.2. Experimental Evidence. It was also Davies’ group who
in 2002 ﬁrst demonstrated that intrathyroidal fetal micro-
chimerism was common and profound in female patients
with Graves’ disease [11]. Renn´ e et al. conﬁrmed these
ﬁndings two years later [14]. Since then, more information
has arisen in the scientiﬁc arena [10].
Davies’ group research was conducted in a sample of 27
thyroid glands from patients with a past medical history of
Graves’ disease [11]. The investigators analyze the presence
of male-speciﬁc SRY gene in maternal thyroid glands by
ELISA-PCR technique for the detection of DNA. This was
a two-step designed study. Initially, male cell assay was
applied to screen for circulating peripheral blood fetal
m i c r o - c h i m e r i s mi n2 0f e m a l e sa n dl a s t l yi ns t o r e dt h y r o i d
tissue. The preliminary results showed that none of 16
never-pregnant females had male cells detected. However, in
previous pregnant women, male cells were easily detected in
28.6%ofbloodsamples.Furthermore,47%offemaleGraves’
blood specimens contained signiﬁcant male cells. These
results were similar to prior reports indicating that periph-
eral blood fetal microchimerism is a common ﬁnding in
childbearing-age women.
A subsequent analysis was focused on thyroid samples
from females previously diagnosed of Graves’ and in a group
of thyroid adenomas as control. The storage of the thyroid
sampleshadbeendiversed.Twentyglandshadbeenprepared
in paraﬃn blocks, whereas the remaining seven were frozen.
Interestingly, SRY gene was found in only 20% of paraﬃn
embedded tissues, while 86% of the frozen samples were
positive for the Y chromosome gene. In the former group,
the ratio of male to female cells ranges from 14 to 295 by
105, with a median of 37/105 male/female cells. SRY gene
was searched in 10 thyroid adenoma specimens (6 in paraﬃn
and 4 frozen). None of the 6 paraﬃn-embedded thyroid ad-
enoma was positive for the SRY gene analysis, whereas 1 outJournal of Thyroid Research 5
Table 1: Summary of the main experimental and clinical ﬁndings of Graves’ disease and microchimerism.
Thyroid tissue origin Storage N Gene and technique Presence of microchimeric cells (%) Reference
Graves’ disease
Paraﬃn-embedded 20 SRY gene by ELISA-PCR 20% Ando et al. [11]
Frozen 7 SRY gene by ELISA-PCR 86% Ando et al. [11]
Paraﬃn-embedded 15 X and Y chromosomes by FISH 40% Renn´ ee ta l .[ 14]
Thyroid adenoma
Paraﬃn-embedded 6 SRY gene by ELISA-PCR 0% Ando et al. [11]
Frozen 4 SRY gene by ELISA-PCR 25% Ando et al. [11]
Paraﬃn-embedded 9 X and Y chromosomes by FISH 22% Renn´ ee ta l .[ 14]
Hashimoto’s thyroiditis Paraﬃn-embedded 25 X and Y chromosomes by FISH 60% Renn´ ee ta l .[ 14]
SRY: sex-determining region Y; PCR: polymerase chain reaction; FISH: ﬂuorescence in situ hybridization.
of 4 frozen samples with thyroid nodules showed male cells.
Authors speculate that the greater detection of the SRY gene
in frozen female thyroid tissues was probably due to DNA
fragmentation in the paraﬃn-derived samples. Unexpect-
edly, many of the patients with male cell-positive thyroids
had no history of earlier male pregnancies at the time of sur-
gery.However,astheauthorsstatedinthediscussion,thisdid
not necessarily exclude the possibility of undetected ﬁrst
trimester pregnancies because it has been demonstrated that
fetal microchimerism can be established in the ﬁrst month of
pregnancy [11, 46].
Renn´ e et al. study compared three entities: Graves’
disease, Hashimoto’s thyroiditis, and nodular or diﬀuse
follicular adenomas from women whose childbirth history
was positive for sons [14]. These investigators screened by
ﬂuorescence in situ hybridization for X chromosome and
Y chromosome speciﬁc staining from paraﬃn-embedded
thyroidspecimentakenatsurgery.Theresultsshowedthat23
out of 49 thyroids (47%) were positive for Y-chromosome-
speciﬁc staining. These authors found no Y-chromosomes-
positive thyrocytes. The proportion of Y-chromosome-
positive thyroid section was highest in Hashimoto’s thy-
roiditis (15/25; 60%), lower in Graves’ disease (6/15; 40%),
and infrequent in follicular adenomas (2/9; 22%) [14].
The results indicate a higher degree of microchimerism in
autoimmune thyroid disease than in benign proliferative
disorder. The results were consistent with previous reports
also showing that microchimeric cells are found in more
subjects with autoimmune thyroid diseases than in any other
thyroid diseases [11, 13].
A summary of these ﬁndings is presented in Table 1.
7. Controversial Studies about the Relationship
between MicrochimerismandAITD
Those dissenting from the appraisal of the relation between
autoimmune thyroid disease and microchimerism mainly
base on data from epidemiological studies. An Australian
study over a large community-based female population
(1,045 participants) showed no association between parity
and presence of thyroid autoantibodies or thyroid dys-
function. Hence, the authors suggested a lesser role of
fetal microchimerism in autoimmune thyroid diseases [47].
A year later, a Danish group also investigated the association
between the presence of circulating thyroid autoantibodies
and previous pregnancy, parity, and the use of estrogens in
an even larger population cohort of 3,712 women. These
authors reinforce the Australian conclusion, as they also did
not ﬁnd any association between thyroid antibodies and
pregnancy. No association was observed between hormonal
replacement therapy and serum TPO antibodies levels either.
In line with the Australian authors, the Danish investigators
concluded that there was no association between previous
pregnancy and serum thyroid Abs level, which argues, in
their opinion, against the role of microchimerism as a trigger
factor of thyroid autoimmunity [48]. These two studies seem
to indicate that the risk of having TPO antibodies or Tg
antibodies was similar in nulliparous women compared with
women with one or more previous pregnancies. However,
recently in 2011, an American study was published with a
confronting conclusion [49]. The authors analyze the rela-
tionship between TPO antibodies and increasing parity in a
population of 17,298 women, larger than the two previous
samples. The authors analyze the relationship of serum
TPO antibody levels and increasing parity. Despite that
the incidence of abnormally elevated TPO antibody levels
increased with advancing parity, this trend was not signiﬁ-
cant after adjustment for maternal characteristics. However
at higher TPO antibody levels, a signiﬁcant relationship
with advancing parity persisted after adjustments. Therefore,
it was concluded that advancing parity is associated with
an increased risk for high serum concentrations of TPO
antibodies, suggesting that fetal microchimerism may play
a role in development of autoimmune thyroid disorders
[49]. The two main results from this large American study
could help to explain why Australian and Danish authors
could not ﬁnd any relationship between parity and presence
of TPO antibody levels. Nevertheless, it remains to be
demonstrated that the establishment of microchimeric cells
openly inﬂuences the natural history of autoimmune thyroid
diseases.
8. Conclusions
Currently, there is a large body of evidence showing that
maternal thyroid gland is a signiﬁcant organ where a variety
of fetal cells settle and persist for decades. These foreign6 Journal of Thyroid Research
immune cells may be activated after delivery once placental
immune suppression is over. This remains an attractive
hypothesis for the postpartum increase of prevalence of
Graves’ disease.
Acknowledgment
The author thanks Professor E. Santiago for reviewing the
paper and for his valuable suggestions.
References
[ 1 ]J .C .G a l o f r ´ e and T. F. Davies, “Microchimerism and thyroid
disease,” 2007, http://www.hotthyroidology.com/.
[2] M. R. Thomas, R. Williamson, I. Craft, N. Yazdani, and C.
H. Rodeck, “Y chromosome sequence DNA ampliﬁed from
peripheral blood of women in early pregnancy,” The Lancet,
vol. 343, no. 8894, pp. 413–414, 1994.
[3] B. Srivatsa, S. Srivatsa, K. L. Johnson, and D. W. Bianchi,
“Maternal cell microchimerism in newborn tissues,” Journal
of Pediatrics, vol. 142, no. 1, pp. 31–35, 2003.
[4] J. Schroder, “Transplacental passage of blood cells,” Journal of
Medical Genetics, vol. 12, no. 3, pp. 230–242, 1975.
[ 5 ]Y .M .D .L o ,E .S .F .L o ,N .W a t s o ne ta l . ,“ T w o - w a yc e l lt r a ﬃc
between mother and fetus: biologic and clinical implications,”
Blood, vol. 88, no. 11, pp. 4390–4395, 1996.
[ 6 ]T .P e t i t ,E .G l u c k m a n ,E .C a r o s e l l a ,Y .B r o s s a r d ,O .B r i s o n ,
and G. Socie, “A highly sensitive polymerase chain reaction
method reveals the ubiquitous presence of maternal cells in
human umbilical cord blood,” Experimental Hematology, vol.
23, no. 14, pp. 1601–1605, 1995.
[7] C. Danae Steele, R. J. Wapner, J. Bruce Smith, M. K. Haynes,
and L. G. Jackson, “Prenatal diagnosis using fetal cells isolated
from maternal peripheral blood: a review,” Clinical Obstetrics
and Gynecology, vol. 39, no. 4, pp. 801–813, 1996.
[8] S. Aractingi, N. Berkane, P. Bertheau et al., “Fetal DNA in skin
of polymorphic eruptions of pregnancy,” The Lancet, vol. 352,
no. 9144, pp. 1898–1901, 1998.
[ 9 ]P .C .E v a n s ,N .L a m b e r t ,S .M a l o n e y ,D .E .F u r s t ,J .M .
Moore, and J. L. Nelson, “Long-term fetal microchimerism in
peripheral blood mononuclear cell subsets in healthy women
and women with scleroderma,” Blood, vol. 93, no. 6, pp. 2033–
2037, 1999.
[10] L.Fugazzola,V.Cirello,andP.Beck-Peccoz,“Fetalmicrochim-
erism as an explanation of disease,” Nature Reviews Endocri-
nology, vol. 7, pp. 89–97, 2011.
[11] T. Ando, M. Imaizumi, P. N. Graves, P. Unger, and T. F. Davies,
“IntrathyroidalfetalmicrochimerisminGraves’disease,”Jour-
nalofClinicalEndocrinologyandMetabolism,v ol.87,no .7,pp .
3315–3320, 2002.
[12] M. Klintschar, P. Schwaiger, S. Mannweiler, S. Regauer, and
M. Kleiber, “Evidence of fetal microchimerism in Hashimoto’s
thyroiditis,” Journal of Clinical Endocrinology and Metabolism,
vol. 86, no. 6, pp. 2494–2498, 2001.
[13] B. Srivatsa, S. Srivatsa, K. L. Johnson, O. Samura, S. L. Lee,
and D. W. Bianchi, “Microchimerism of presumed fetal origin
in thyroid specimens from women: a case-control study,” The
Lancet, vol. 358, no. 9298, pp. 2034–2038, 2001.
[14] C. Renn´ e, E. R. Lopez, S. A. Steimle-Grauer et al., “Thy-
roid fetal male microchimerisms in mothers with thyroid
disorders: presence of Y-chromosomal immunoﬂuorescence
in thyroid-inﬁltrating lymphocytes is more prevalent in
Hashimoto’s thyroiditis and graves’ disease than in follicular
adenomas,” Journal of Clinical Endocrinology and Metabolism,
vol. 89, no. 11, pp. 5810–5814, 2004.
[15] T. Klonisch and R. Drouin, “Fetal-maternal exchange of mul-
tipotent stem/progenitor cells: microchimerism in diagnosis
and disease,” Trends in Molecular Medicine, vol. 15, no. 11, pp.
510–518, 2009.
[16] K. M. Adams Waldorf and J. L. Nelson, “Autoimmune dis-ease
during pregnancy and the microchimerism legacy of preg-
nancy,” Immunological Investigations, vol. 37, no. 5-6, pp. 631–
644, 2008.
[17] J. L. Nelson, “Maternal-fetal immunology and autoimmune
disease: is some autoimmune disease auto-alloimmune or
allo-autoimmune?” Arthritis and Rheumatism,v o l .3 9 ,n o .2 ,
pp. 191–194, 1996.
[ 1 8 ]A .S t a g n a r o - G r e e n ,S .H .R o m a n ,R .H .C o b i n ,E .E l - H a r a z y ,
S. Wallenstein, and T. F. Davies, “A prospective study of
lymphocyte-initiated immunosuppression in normal preg-
nancy: evidence of a T-cell etiology for postpartum
thyroid dysfunction,” Journal of Clinical Endocrinology and
Metabolism, vol. 74, no. 3, pp. 645–653, 1992.
[19] T.AndoandT.F.Davies,“Self-recognitionandtheroleoffetal
microchimerism,”BestPracticeandResearch,vol.18,no.2,pp.
197–211, 2004.
[20] A. Stagnaro-Green, M. Abalovich, E. Alexander et al., “Guide-
lines of the American Thyroid Association for the diagnosis
and management of thyroid disease during pregnancy and
postpartum,” Thyroid, vol. 21, no. 10, pp. 1081–1125, 2011.
[21] T. Ando and T. F. Davies, “Postpartum autoimmune thyroid
disease: the potential role of fetal microchimerism,” Journal
of Clinical Endocrinology and Metabolism,v o l .8 8 ,n o .7 ,p p .
2965–2971, 2003.
[22] A. Stagnaro-Green, A. Schwartz, R. Gismondi, A. Tinelli, T.
Mangieri, and R. Negro, “High rate of persistent hypothy-
roidism in a large-scale prospective study of postpartum
thyroiditis in Southern Italy,” Journal of Clinical Endocrinology
and Metabolism, vol. 96, no. 3, pp. 652–657, 2011.
[23] R. Jansson, P. A. Dahlberg, B. Winsa, O. Meirik, J. Safwenberg,
and A. Karlsson, “The postpartum period constitutes an
important risk for the development of clinical Graves’ disease
in young women,” Acta Endocrinologica, vol. 116, no. 3, pp.
321–325, 1987.
[24] W. J. Burlingham, “A lesson in tolerance—maternal instruc-
tion to fetal cells,” New England Journal of Medicine, vol. 360,
no. 13, pp. 1282–1357, 2009.
[25] J. C. Galofre and T. F. Davies, “Autoimmune thyroid disease in
pregnancy: a review,” Journal of Women’s Health, vol. 18, no.
11, pp. 1847–1856, 2009.
[26] T. F. Davies, “The thyroid immunology of the postpartum
period,” Thyroid, vol. 9, no. 7, pp. 675–684, 1999.
[27] M. Imaizumi, A. Pritsker, M. Kita, L. Ahmad, P. Unger, and
T.F.Davies,“Pregnancyandmurinethyroiditis:thyroglobulin
immunizationleadstofetallossinspeciﬁcallogeneicpregnan-
cies,” Endocrinology, vol. 142, no. 2, pp. 823–829, 2001.
[28] J. L. Nelson, D. E. Furst, S. Maloney et al., “Microchimerism
and HLA-compatible relationships of pregnancy in sclero-
derma,” The Lancet, vol. 351, no. 9102, pp. 559–562, 1998.
[29] C. M. Artlett, J. B. Smith, and S. A. Jimenez, “Identiﬁcation of
fetal DNA and cells in skin lesions from women with systemic
sclerosis,” New England Journal of Medicine, vol. 338, no. 17,
pp. 1186–1191, 1998.
[30] C. M. Artlett, “Pathophysiology of fetal microchimeric cells,”
Clinica Chimica Acta, vol. 360, no. 1-2, pp. 1–8, 2005.Journal of Thyroid Research 7
[31] J. L. Nelson, K. M. Gillespie, N. C. Lambert et al., “Maternal
microchimerism in peripheral blood in type 1 diabetes and
pancreatic islet β cell microchimerism,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 5, pp. 1637–1642, 2007.
[ 3 2 ]A .S t a g n a r o - G r e e n ,S .H .R o m a n ,R .H .C o b i n ,E .E l - H a r a z y ,
A. Alvarez-Marfany, and T. F. Davies, “Detection of at-risk
pregnancy by means of highly sensitive assays for thyroid
autoantibodies,” Journal of the American Medical Association,
vol. 264, no. 11, pp. 1422–1425, 1990.
[33] T. Klonisch and R. Drouin, “Fetal-maternal exchange of mul-
tipotent stem/progenitor cells: microchimerism in diagnosis
and disease,” Trends in Molecular Medicine, vol. 15, no. 11, pp.
510–518, 2009.
[34] R.P.Miech,“Theroleoffetalmicrochimerisminautoimmune
disease,” International Journal of Clinical and Experimental
Medicine, vol. 3, no. 2, pp. 164–168, 2010.
[35] M.I maizumi,A.P ritsk e r ,P .U ng e r ,andT .F .Da vies,“I ntrath y-
roidal fetal microchimerism in pregnancy and postpartum,”
Endocrinology, vol. 143, no. 1, pp. 247–253, 2002.
[36] K. Badenhoop, “Intrathyroidal microchimerism in Graves’
disease or Hashimoto’s thyroiditis: regulation of tolerance
or alloimmunity by fetal-maternal immune interactions?”
European Journal of Endocrinology, vol. 150, no. 4, pp. 421–
423, 2004.
[37] M.Klintschar,U.D.Immel,A.Kehlenetal.,“Fetalmicrochim-
erism in Hashimoto’s thyroiditis: a quantitative approach,”
European Journal of Endocrinology, vol. 154, no. 2, pp. 237–
241, 2006.
[38] V. Cirello, M. P. Recalcati, M. Muzza et al., “Fetal cell micro-
chimerisminpapillarythyroidcancer:apossibleroleintumor
damage and tissue repair,” Cancer Research, vol. 68, no. 20, pp.
8482–8488, 2008.
[39] A. W. C. Kung and B. M. Jones, “A change from stimulatory
to blocking antibody activity in Graves’ disease during preg-
nancy,” Journal of Clinical Endocrinology and Metabolism, vol.
83, no. 2, pp. 514–518, 1998.
[40] N. Amino, Y. Izumi, Y. Hidaka et al., “No increase of blocking
typeanti-thyrotropinreceptorantibodiesduringpregnancyin
patients with graves’ disease,” Journal of Clinical Endocrinology
and Metabolism, vol. 88, no. 12, pp. 5871–5874, 2003.
[41] S. J. Mandel, C. A. Spencer, and J. G. Hollowell, “Are detection
and treatment of thyroid insuﬃciency in pregnancy feasible?”
Thyroid, vol. 15, no. 1, pp. 44–53, 2005.
[42] J. H. Lazarus, “Epidemiology and prevention of thyroid dis-
ease in pregnancy,” Thyroid, vol. 12, no. 10, pp. 861–865, 2002.
[43] A. P. Weetman, “Immunity, thyroid function and pregnancy:
molecular mechanisms,” Nature Reviews Endocrinology, vol. 6,
no. 6, pp. 311–318, 2010.
[44] Y. Nakagawa, K. Mori, S. Hoshikawa, M. Yamamoto, S. Ito,
and K. Yoshida, “Postpartum recurrence of Graves’ hyperthy-
roidism can be prevented by the continuation of antithyroid
drugs during pregnancy,” Clinical Endocrinology, vol. 57, no.
4, pp. 467–471, 2002.
[45] D.B.RochesterandT.F.Davies,“IncreasedriskofGraves’dis-
ease after pregnancy,” Thyroid, vol. 15, no. 11, pp. 1287–1290,
2005.
[46] M. R. Thomas, R. Williamson, I. Craft, N. Yazdani, and C.
H. Rodeck, “Y chromosome sequence DNA ampliﬁed from
peripheral blood of women in early pregnancy,” The Lancet,
vol. 343, no. 8894, pp. 413–414, 1994.
[47] J. P. Walsh, A. P. Bremner, M. K. Bulsara et al., “Parity and the
risk of autoimmune thyroid disease: a community-based
study,” Journal of Clinical Endocrinology and Metabolism,
vol. 90, no. 9, pp. 5309–5312, 2005.
[48] I. B. Pedersen, P. Laurberg, N. Knudsen et al., “Lack of as-
sociation between thyroid autoantibodies and parity in a pop-
ulation study argues against microchimerism as a trigger of
thyroid autoimmunity,” European Journal of Endocrinology,
vol. 154, no. 1, pp. 39–45, 2006.
[49] L. G. Greer, B. M. Casey, L. M. Halvorson, C. Y. Spong, D. D.
McIntire, and F. G. Cunningham, “Antithyroid antibodies and
parity: further evidence for microchimerism in autoimmune
thyroid disease,” American Journal of Obstetrics and Gynecol-
ogy, vol. 205, no. 5, pp. 471.e1–471.e4, 2011.